中性粒细胞与淋巴细胞比值作为接受表皮生长因子受体酪氨酸激酶抑制剂治疗的非小细胞肺癌患者的预后参数：一项系统评价和荟萃分析

Neutrophil-Lymphocyte Ratio as a Prognostic Parameter in NSCLC Patients Receiving EGFR-TKIs: A Systematic Review and Meta-Analysis.

作者信息

Tang Mingbo, Gao Xinliang, Sun He, Tian Suyan, Dong Junxue, Liu Zhao, Liu Wei

机构信息

Department of Thoracic Surgery, The First Hospital of Jilin University, Changchun 130021, Jilin, China.

Department of Division of Clinical Research, The First Hospital of Jilin University, Changchun 130021, Jilin, China.

出版信息

J Oncol. 2021 Jan 20;2021:6688346. doi: 10.1155/2021/6688346. eCollection 2021.

DOI:10.1155/2021/6688346

PMID:33542732

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7840257/

Abstract

OBJECTIVE

To research the impact of neutrophil-lymphocyte ratio (NLR) as a prognostic parameter in non-small-cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).

METHODS

We searched the databases such as the American Society of Clinical Oncology (ASCO), EMBASE, PubMed, the European Society of Medical Oncology (ESMO), Wanfang, and CNKI for articles illustrating the impact of pretreatment NLR on survival data in NSCLC patients undergoing EGFR-TKIs treatment. We did a meta-analysis for overall survival (OS) and progression-free survival (PFS).

RESULTS

We recruited 10 studies in our meta-analysis. Our study suggested that patients with low NLR had better PFS (hazard ratio (HR) = 1.67, 95% confidence interval (CI) = (1.16-2.39), and value = 0.005) and OS (HR = 1.66, 95% CI = (1.08-2.55), and value = 0.02) in comparison to patients with high NLR.